CluePoints

Agentic AI is creating real buzz in clinical trials, but will it deliver? In areas like medical coding and data management, it could boost productivity by up to 60%. And as Usama says, agentic AI isn’t a replacement for human expertise, t’s an amplifier. hubs.ly/Q047Xs330

Everyone understands RBQM in theory. Far fewer actually do it. Still reducing RBQM to KRI lists and SDV reductions? ICH E6(R3) moved the goalposts. We updated our Ultimate Guide for ICH E6(R3). Practical, not theoretical. hubs.ly/Q047zh0C0

CluePoints is onsite at #ACDM26 in Berlin! Sas Maheswaran presented earlier on LLM-driven scenario analysis. If you missed it, visit Booth 40. Later today: Marta Kowalska (CluePoints) & Jennifer Nielsen (Lundbeck) will be speaking on “Getting Started with RBQM/ATR” at 5:45PM.

Informed consent under ICH E6(R3) is no longer just a signature on a form. It's a continuous, participant-centered process — with real implications for sponsors and CROs. Part 4 of our ICH E6(R3) Demystified series is now live 👇 hubs.ly/Q046x7Pq0

Investing in women isn't a subtraction — it's an intentional multiplication. 🌱 Our CPO Sinead Godkin shares her perspective on pay-it-forward leadership this #IWD2026 in @pharmaphorum: hubs.ly/Q0462NKl0 #WhenWomenThrive #WomeninSTEM #CluePoints

Join Marta Kowalska (CluePoints) & Jennifer Neilson (Lundbeck) on March 16, 5:45–6:15 PM for Getting Started with RBQM / ATR — and see how smarter oversight drives inspection readiness and stronger data quality. 👉 Secure your place here: hubs.ly/Q045xZrG0

Tools don’t transform trials. People do. On March 15 (5:15–6:45pm) at #ACDM26 in Berlin, Tessa Barrett (CluePoints) joins the “Bridging the Behaviour Gap” workshop to explore how teams adapt and how real change happens in clinical data management. Join us: hubs.ly/Q044dN9s0

Snow day reading? ❄️ Part 3 of our #ICHE6R3 series breaks down Quality Tolerance Limits (QTLs) — and why they’re central to proactive, risk-based oversight. Defining QTLs is easy. Monitoring them intelligently is the real shift. 🔗 hubs.ly/Q044cPR20

$40M. That was the projected cost of 100% on-site + 100% SDV in a global Phase IV oncology study. Familiar? Yes. Necessary? Not anymore. A CRO explored a hybrid RBQM model powered by CluePoints. See what happened next : hubs.ly/Q043CgYJ0

One month to go until ACDM 2026 in Berlin! Visit CluePoints at Booth #40 to see how IQD, IMC, and CMP support risk-based data management – helping teams focus on the right data, raise better queries, and stay inspection-ready.

From line listings to LLM-driven insight. Don’t miss Sas Maheswaran, Market Owner, Clinical Data Strategy at CluePoints, speaking at ACDM: Continue the conversation with us at booth #40. Session details: hubs.ly/Q043nW5K0

ICH E6(R3) isn’t just a revision, it’s a reset for clinical trial oversight. Risk-based management, quality-by-design, and centralized monitoring are no longer optional. Are you reacting to risk… or designing it out? Read Dan’s perspective 👇 hubs.ly/Q043nfQ-0

Clinical Data Managers: #ACDM26 is where what’s next gets real. March 15–17 in Berlin, Europe’s largest CDM event. Find CluePoints at Booth #40 and see how IMC + IQD move teams beyond line listings to proactive, risk-based data oversight. connect: hubs.ly/Q042hC_D0

A big congratulations to Lynn, our giveaway winner at SCOPE US! Thanks to everyone who stopped by the CluePoints booth, spent time with our team, and entered the giveaway. We appreciated the opportunity to connect and discuss practical ways to run smarter, safer clinical trials.

Day 1 at #SCOPE is off to a strong start. Great conversations. Smart people. Real momentum. Stop by Booth 1107 to meet the CluePoints team and see IQD in action.

Last chance to join us! Spend your evening networking with CluePoints and IgniteData at Topgolf Orlando. 📅 Tuesday, February 3rd | 7–10 PM Food, drinks, great company, and plenty of swings—register now before spots fill up. 👉 Register now: hubs.ly/Q041gcWp0

We’re exhibiting tomorrow at #SCOPEUS2026. Visit CluePoints at Booth 1107 to see how AI-powered oversight helps sponsors and CROs spot risk earlier and stay regulatory-ready. Stop by for a chance to win Ray-Ban Meta AI sunglasses 😎

In Part 1, we explored how ICH E6(R3) shifts the industry toward quality by design. Part 2 goes deeper: not all data is equal. Defining what’s Critical to Quality is how RBQM becomes practical — and meaningful. 🔗 hubs.ly/Q040T-RT0

We’re excited to connect with clinical ops, data management & quality leaders at #SCOPE! See how AI-powered oversight helps teams focus on what matters most from RBQM to integrated data review. Visit Booth 1107 to win Ray-Ban Meta AI sunglasses.

53% of all COAs are now electronic. But if two patients complete their eDiary at the exact same time—every day—would you notice? Our new white paper shows how advanced analytics uncover eCOA risks traditional monitoring can’t. Read here: hubs.ly/Q040J2Zv0